Delavirdine Mesylate(dell ah vur’ den)
Rescriptor
PREGNANCY CATEGORY C
Drug Classes
Antiviral
Nonnucleoside reverse transcriptase inhibitor
Therapeutic Actions
Non-nucleoside inhibitor of HIV reverse transcriptase; binds directly to HIV’s reverse transcriptase and blocks RNA-dependent and DNA-dependent DNA polymerase activities.
Indications
Treatment of HIV-1 infection in combination with other appropriate retroviral drugs when therapy is warranted; not intended as a monotherapy because resistant virus emerges rapidly
Contraindications and Cautions
Contraindicated with life-threatening allergy to any component.
Use cautiously with compromised or impaired liver function, pregnancy, lactation.
Available Forms
Tablets—100, 200 mg
Dosages
Adults and patients older than 16 yr
400 mg PO tid used in combination with appropriate antiretroviral drugs.
Pediatric patients
Not recommended for patients younger than 16 yr.
Pharmacokinetics
|
Metabolism: Hepatic; T1/2: 2–11 hr
Distribution: May cross placenta; may enter breast milk
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
